Bevacizumab versus ranibizumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE study

Rithwick Rajagopal, Gaurav K. Shah, Kevin J. Blinder, Michael Altaweel, Dean Eliott, Raymond Wee, Blake Cooper, Harpreet Walia, Bradley Smith, Daniel P. Joseph

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Background and Objective: To compare efficacy of monthly treatment with bevacizumab or ranibizumab for macular edema due to retinal vein occlusion. Patients and Methods: Randomized, multicenter, comparative trial (ClinicalTrials.gov identifier: NCT01428388). Participants were randomized 1:1 to receive monthly treatment with bevacizumab or ranibizumab. The primary outcome was change in central foveal thickness at 6 months compared to baseline. Results: The trial randomized 98 patients to treatment with bevacizumab or ranibizumab. At 6 months, there were no differences in change in central foveal thickness between groups (bevacizumab: mean reduction of 212.6 μm, 95% confidence interval [CI], -288.3 to -137.0; ranibizumab: mean reduction of 243.8 μm, 95% CI, -309.6 to -178.0; P = .72, analysis of variance [ANOVA]). Both groups showed similar functional outcomes (bevacizumab: 0.33 logMAR gain, 95% CI, -0.47 to -0.18; ranibizumab: 0.34 log- MAR gain, 95% CI, -0.45 to -0.23; P = .38, ANOVA). Conclusion: In the treatment of retinal vein occlusion, bevacizumab and ranibizumab have similar effects on reducing macular thickness and improving visual acuity.

Original languageEnglish
Pages (from-to)844-850
Number of pages7
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume46
Issue number8
DOIs
StatePublished - Sep 1 2015

Fingerprint Dive into the research topics of 'Bevacizumab versus ranibizumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE study'. Together they form a unique fingerprint.

  • Cite this